{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T18:51:49Z","timestamp":1788634309172,"version":"build-2803163510"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["23 2645 PjF 01H"],"award-info":[{"award-number":["23 2645 PjF 01H"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 21 1485 Pj"],"award-info":[{"award-number":["CAN 21 1485 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ProstateCancerfonden"},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-00556"],"award-info":[{"award-number":["2022-00556"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Bombesin analogues are gaining popularity as GRPR-targeting theranostic agents aiming to provide molecular tools for a patient-tailored management. We previously reported on two series of DOTAGA-bearing GRPR-antagonists, based on either [NMe-Gly<jats:sup>11<\/jats:sup>]RM26 (DOTAGA-X-DPhe-Gln-Trp-Ala-Val-NMe-Gly-His-Sta-Leu-NH<jats:sub>2<\/jats:sub>) or on DB15 (DOTAGA-X-SAR; SAR: DPhe-Gln-Trp-Ala-Val-NMe-Gly-His-Leu-NHEt) motifs, which were preclinically screened after labelling with In-111. In the current study, we aimed to evaluate in vitro and in vivo the four best-performing agents, AU-RM26-M2 (X: PEG2-Pip; Pip: 4-amino-1-carboxymethyl-piperidine), AU-RM26-M4 (X: Arg-Arg-Pip), AU-SAR-M1 (X: AMA-DIG; AMA: p-amino methylaniline, DIG: diglycolate) and AU-SAR-M2 (Arg-AMA-DIG), this time labelled with the therapeutic radionuclide Lu-177.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>All four [<jats:sup>177<\/jats:sup>Lu]Lu-peptide radioligands displayed highly GRPR-mediated cellular uptake, showing the typical profile of radioantagonists, with the bulk of cell-associated radioactivity being membrane-bound. The analogues demonstrated good in vivo stability, which was however further improved by in situ stabilization induced\u00a0by pretreatment of animals\u00a0with Entresto as the source of the potent neprilysin (NEP)-inhibitor sacubitrilat. The biodistribution profile of the four radiopeptides was determined in prostate cancer PC-3 xenograft-bearing mice at 4\u00a0h and 23\u00a0h pi, after Entresto pre-treatment. All peptide radioligands had a rapid clearance from the background tissues, with the highest activity uptake found in the implanted tumours, the kidneys and to a lesser extent the GRPR-rich pancreas. The activity in the pancreas and, on a smaller scale, in the kidneys was washed out by 23\u00a0h pi, while being highly retained in the tumours. Among the tested analogues, [<jats:sup>177<\/jats:sup>Lu]Lu-AU-SAR-M1 displayed the overall most favourable properties, combining the lowest retention in the kidneys with high and prolonged activity accumulation in the tumours. As a result, [<jats:sup>177<\/jats:sup>Lu]Lu-AU-SAR-M1 provided the best area under the curve (AUC) ratio between tumour and kidneys (5.4), in comparison with [<jats:sup>177<\/jats:sup>Lu]Lu-AU-SAR-M2 (3.8), [<jats:sup>177<\/jats:sup>Lu]Lu-AU-RM26-M4 (3.4), and [<jats:sup>177<\/jats:sup>Lu]Lu-AU-RM26-M2 (1.1).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In conclusion, these results qualify [<jats:sup>177<\/jats:sup>Lu]Lu-AU-SAR-M1 as the candidate of choice for further evaluation in a dedicated preclinical radiotherapy study.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41181-025-00374-3","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T23:11:46Z","timestamp":1754003506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["RM2 and DB15 analogues bearing [177Lu]Lu-DOTAGA via different linkers, as radiotherapeutics: a head-to-head comparative study"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0617-3936","authenticated-orcid":false,"given":"Panagiotis","family":"Kanellopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Bitzios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Zelepukin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Bezverkhniaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodosia","family":"Maina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold A.","family":"Nock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Tolmachev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Orlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"issue":"7","key":"374_CR1","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.3390\/biom13071134","volume":"13","author":"A Abouzayed","year":"2023","unstructured":"Abouzayed A, Kanellopoulos P, Gorislav A, Tolmachev V, Maina T, Nock BA, et al. Preclinical characterization of a stabilized gastrin-releasing peptide receptor antagonist for targeted cancer theranostics. Biomolecules. 2023;13(7):1134.","journal-title":"Biomolecules"},{"issue":"11","key":"374_CR2","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.2967\/jnumed.120.258814","volume":"62","author":"IL Bakker","year":"2021","unstructured":"Bakker IL, Fr\u00f6berg AC, Busstra MB, Verzijlbergen JF, Konijnenberg M, van Leenders GJLH, et al. GRPr antagonist 68Ga-SB3 PET\/CT imaging of primary prostate cancer in therapy-na\u00efve patients. J Nucl Med. 2021;62(11):1517\u201323. https:\/\/doi.org\/10.2967\/jnumed.120.258814.","journal-title":"J. Nucl Med"},{"issue":"1","key":"374_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00259-019-04503-4","volume":"47","author":"L Baratto","year":"2020","unstructured":"Baratto L, Duan H, Laudicella R, Toriihara A, Hatami N, Ferri V, et al. Physiological 68Ga-RM2 uptake in patients with biochemically recurrent prostate cancer: an atlas of semi-quantitative measurements. Eur J Nucl Med Mol Imaging. 2020;47(1):115\u201322. https:\/\/doi.org\/10.1007\/s00259-019-04503-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"374_CR4","first-page":"79PLP","volume":"48","author":"R Baum","year":"2007","unstructured":"Baum R, Prasad V, Mutloka N, Frischknecht M, Maecke H, Reubi J. Molecular imaging of bombesin receptors in various tumors by Ga-68 AMBA PET\/CT: first results. J Nucl Med. 2007;48:79PLP-79P.","journal-title":"J Nucl Med"},{"issue":"2","key":"374_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1053\/j.semnuclmed.2024.01.004","volume":"54","author":"C Baun","year":"2024","unstructured":"Baun C, Naghavi-Behzad M, Hildebrandt MG, Gerke O, Thisgaard H. Gastrin-releasing peptide receptor as a theranostic target in breast cancer: a systematic scoping review. Semin Nucl Med. 2024;54(2):256\u201369.","journal-title":"Semin Nucl Med"},{"issue":"1","key":"374_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s00330-022-08982-2","volume":"33","author":"M Beheshti","year":"2022","unstructured":"Beheshti M, Taimen P, Kemppainen J, Jambor I, M\u00fcller A, Loidl W, et al. Value of 68Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI\u2014a phase I\/II study. Eur Radiol. 2022;33(1):472\u201382. https:\/\/doi.org\/10.1007\/s00330-022-08982-2.","journal-title":"Eur Radiol"},{"issue":"1","key":"374_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13550-025-01204-y","volume":"15","author":"A Bj\u00e4reback","year":"2025","unstructured":"Bj\u00e4reback A, Jonmarker O, Tzortzakakis A, Jussing E, Li C, Altena R, et al. First-in-human experience with GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in prostate and breast cancer patients using PET\/CT. EJNMMI Res. 2025;15(1):12. https:\/\/doi.org\/10.1186\/s13550-025-01204-y.","journal-title":"EJNMMI Res"},{"key":"374_CR8","first-page":"S221","volume":"34","author":"L Bodei","year":"2007","unstructured":"Bodei L, Ferrari M, Nunn A, Llull J, M. C, Martano L, et al. 177Lu-AMBA bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations. Eur J Nucl Med Mol Imaging. 2007;34:S221.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"374_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.2967\/jnumed.107.045054","volume":"49","author":"R Cescato","year":"2008","unstructured":"Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49(2):318\u201326. https:\/\/doi.org\/10.2967\/jnumed.107.045054.","journal-title":"J Nucl Med"},{"issue":"6","key":"374_CR10","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.3390\/cancers15061631","volume":"15","author":"V Chernov","year":"2023","unstructured":"Chernov V, Rybina A, Zelchan R, Medvedeva A, Bragina O, Lushnikova N, et al. Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a bombesin analogue antagonistic to gastrin-releasing peptide receptors (GRPRs), for SPECT imaging of GRPR expression in malignant tumors. Cancers (Basel). 2023;15(6):1631.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"374_CR11","doi-asserted-by":"publisher","first-page":"S823","DOI":"10.1007\/s00259-024-06939-9","volume":"52","author":"A Csismazia","year":"2024","unstructured":"Csismazia A, Tzortzakakis A, Al E. Estrogen-positive metastatic breast cancer examined with [68Ga]Ga-NOTA-PEG2-RM26 PET\/CT\u2013first in human experience. Eur J Nucl Med Mol Imaging. 2024;52(1):S823-824. https:\/\/doi.org\/10.1007\/s00259-024-06939-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"374_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1250799\/full","author":"A D\u2019Onofrio","year":"2023","unstructured":"D\u2019Onofrio A, Engelbrecht S, L\u00e4ppchen T, Rominger A, Gourni E. GRPR-targeting radiotheranostics for breast cancer management. Front Med. 2023. https:\/\/doi.org\/10.3389\/fmed.2023.1250799\/full.","journal-title":"Front. Med."},{"issue":"2","key":"374_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2967\/jnumed.116.176636","volume":"58","author":"SU Dalm","year":"2017","unstructured":"Dalm SU, Bakker IL, de Blois E, Doeswijk GN, Konijnenberg MW, Orlandi F, et al. 68Ga\/ 177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology. J Nucl Med. 2017;58(2):293\u20139. https:\/\/doi.org\/10.2967\/jnumed.116.176636.","journal-title":"J Nucl Med"},{"issue":"3","key":"374_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.cpet.2024.03.004","volume":"19","author":"S Dalm","year":"2024","unstructured":"Dalm S, Duan H, Iagaru A. Gastrin releasing peptide receptors-targeted PET diagnostics and radionuclide therapy for prostate cancer management. PET Clin. 2024;19(3):401\u201315.","journal-title":"PET Clin"},{"issue":"13","key":"374_CR15","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1007\/s00259-023-06364-4","volume":"50","author":"TST Damiana","year":"2023","unstructured":"Damiana TST, Para\u00efso P, de Ridder C, Stuurman D, Seimbille Y, Dalm SU. Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting. Eur J Nucl Med Mol Imaging. 2023;50(13):3851\u201361. https:\/\/doi.org\/10.1007\/s00259-023-06364-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"374_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/1040-8428(96)00220-X","volume":"24","author":"R de Castiglione","year":"1996","unstructured":"de Castiglione R, Gozzini L. Bombesin receptor antagonists. Crit Rev Oncol Hematol. 1996;24(2):117\u201351.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"374_CR17","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2967\/jnumed.123.267017","volume":"65","author":"H Duan","year":"2024","unstructured":"Duan H, Song H, Davidzon GA, Moradi F, Liang T, Loening A, et al. Prospective comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET\/MRI in patients with biochemically recurrent prostate cancer. J Nucl Med. 2024;65(6):897\u2013903.","journal-title":"J Nucl Med"},{"issue":"5","key":"374_CR18","doi-asserted-by":"publisher","first-page":"762","DOI":"10.2967\/jnumed.112.112169","volume":"54","author":"RA Dumont","year":"2013","unstructured":"Dumont RA, Tamma M, Braun F, Borkowski S, Reubi JC, Maecke H, et al. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin. J Nucl Med. 2013;54(5):762\u20139. https:\/\/doi.org\/10.2967\/jnumed.112.112169.","journal-title":"J Nucl Med"},{"issue":"1\u20132","key":"374_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000151616","volume":"75","author":"CB Farias","year":"2008","unstructured":"Farias CB, Lima RC, Lima LO, Flores DG, Meurer L, Brunetto AL, et al. Stimulation of proliferation of U138-MG glioblastoma cells by gastrin-releasing peptide in combination with agents that enhance cAMP signaling. Oncology. 2008;75(1\u20132):27\u201331. https:\/\/doi.org\/10.1159\/000151616.","journal-title":"Oncology"},{"issue":"3","key":"374_CR20","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00259-023-06483-y","volume":"51","author":"S Ghezzo","year":"2024","unstructured":"Ghezzo S, Mapelli P, Samanes Gajate AM, Palmisano A, Cucchiara V, Brembilla G, et al. Diagnostic accuracy of fully hybrid [68Ga]Ga-PSMA-11 PET\/MRI and [68Ga]Ga-RM2 PET\/MRI in patients with biochemically recurrent prostate cancer: a prospective single-center phase II clinical trial. Eur J Nucl Med Mol Imaging. 2024;51(3):907\u201318. https:\/\/doi.org\/10.1007\/s00259-023-06483-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"374_CR21","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.2967\/jnumed.119.238808","volume":"61","author":"L Gruber","year":"2020","unstructured":"Gruber L, Jim\u00e9nez-Franco LD, Decristoforo C, Uprimny C, Glatting G, Hohenberger P, et al. MITIGATE-NeoBOMB1, a phase I\/IIa study to evaluate safety, pharmacokinetics, and preliminary imaging of 68Ga-NeoBOMB1, a gastrin-releasing peptide receptor antagonist, in GIST patients. J Nucl Med. 2020;61(12):1749\u201355.","journal-title":"J Nucl Med"},{"issue":"11","key":"374_CR22","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.3390\/biomedicines10112899","volume":"10","author":"L Gruber","year":"2022","unstructured":"Gruber L, Decristoforo C, Uprimny C, Hohenberger P, Schoenberg SO, Orlandi F, et al. Imaging properties and tumor targeting of 68Ga-NeoBOMB1, a gastrin-releasing peptide receptor antagonist GIST Patients. Biomedicines. 2022;10(11):2899.","journal-title":"Biomedicines"},{"issue":"4","key":"374_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0091270009343932","volume":"50","author":"J Gu","year":"2010","unstructured":"Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor\u2014neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50(4):401\u201314. https:\/\/doi.org\/10.1177\/0091270009343932.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"374_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s41181-020-00115-8","volume":"5","author":"M Hofstetter","year":"2020","unstructured":"Hofstetter M, Moon ES, D\u2019Angelo F, Geissb\u00fchler L, Alberts I, Afshar-Oromieh A, et al. Effect of the versatile bifunctional chelator AAZTA5 on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonist. EJNMMI Radiopharm Chem. 2020;5(1):29. https:\/\/doi.org\/10.1186\/s41181-020-00115-8.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"47","key":"374_CR25","doi-asserted-by":"publisher","first-page":"18671","DOI":"10.1073\/pnas.0709455104","volume":"104","author":"F Hohla","year":"2007","unstructured":"Hohla F, Schally AV, Kanashiro CA, Buchholz S, Baker B, Kannadka C, et al. Growth inhibition of non-small-cell lung carcinoma by BN\/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt. Proc Natl Acad Sci. 2007;104(47):18671\u20136. https:\/\/doi.org\/10.1073\/pnas.0709455104.","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"374_CR26","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3390\/pharmaceutics12121145","volume":"12","author":"P Kanellopoulos","year":"2020","unstructured":"Kanellopoulos P, Kaloudi A, Rouchota M, Loudos G, de Jong M, Krenning EP, et al. One step closer to clinical translation: enhanced tumor targeting of [99mTc]Tc-DB4 and [111In]In-SG4 in mice treated with entresto. Pharmaceutics. 2020;12(12):1145.","journal-title":"Pharmaceutics"},{"issue":"1","key":"374_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s41181-024-00242-6","volume":"9","author":"P Kanellopoulos","year":"2024","unstructured":"Kanellopoulos P, Mattsson A, Abouzayed A, Obeid K, Nock BA, Tolmachev V, et al. Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology. EJNMMI Radiopharm Chem. 2024;9(1):13. https:\/\/doi.org\/10.1186\/s41181-024-00242-6.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"S1","key":"374_CR28","doi-asserted-by":"publisher","first-page":"S279","DOI":"10.1007\/s00259-024-06838-z","volume":"51","author":"J Kurth","year":"2024","unstructured":"Kurth J, Al E. GRPr antagonist [177Lu]Lu-AMTG for treatment of in prostate cancer patients: first in-human biodistribution, in vivo stability, and dosimetry. Eur J Nucl Med Mol Imaging. 2024;51(S1):S279-280. https:\/\/doi.org\/10.1007\/s00259-024-06838-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"374_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00259-019-04504-3","volume":"47","author":"J Kurth","year":"2020","unstructured":"Kurth J, Krause BJ, Schwarzenb\u00f6ck SM, Bergner C, Hakenberg OW, Heuschkel M. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47(1):123\u201335. https:\/\/doi.org\/10.1007\/s00259-019-04504-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"374_CR30","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2967\/jnumed.124.267881","volume":"65","author":"S Li","year":"2024","unstructured":"Li S, Nguyen A, Counter W, John NC, De Leon J, Hruby G, et al. Utility of 64Cu-Sarcophagine-Bombesin PET\/CT in men with biochemically recurrent prostate cancer and negative or equivocal findings on 68Ga-PSMA-11 PET\/CT. J Nucl Med. 2024;65(9):1371\u20135. https:\/\/doi.org\/10.2967\/jnumed.124.267881.","journal-title":"J Nucl Med"},{"issue":"6","key":"374_CR31","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1021\/bc9000189","volume":"20","author":"KE Linder","year":"2009","unstructured":"Linder KE, Metcalfe E, Arunachalam T, Chen J, Eaton SM, Feng W, et al. In vitro and in vivo metabolism of Lu-AMBA, a GRP-receptor binding compound, and the synthesis and characterization of its metabolites Bioconjug. Chem. 2009;20(6):1171\u20138. https:\/\/doi.org\/10.1021\/bc9000189.","journal-title":"Chem."},{"issue":"5","key":"374_CR32","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1021\/acs.bioconjchem.8b00225","volume":"29","author":"E Lymperis","year":"2018","unstructured":"Lymperis E, Kaloudi A, Sallegger W, Bakker IL, Krenning EP, de Jong M, et al. Radiometal-dependent biological profile of the radiolabeled gastrin-releasing peptide receptor antagonist SB3 in cancer theranostics: metabolic and biodistribution patterns defined by neprilysin Bioconjug. Chem. 2018;29(5):1774\u201384. https:\/\/doi.org\/10.1021\/acs.bioconjchem.8b00225.","journal-title":"Chem"},{"issue":"10","key":"374_CR33","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/jlcr.3733","volume":"62","author":"E Lymperis","year":"2019","unstructured":"Lymperis E, Kaloudi A, Kanellopoulos P, Krenning EP, de Jong M, Maina T, et al. Comparative evaluation of the new GRPR-antagonist 111In-SB9 and 111In-AMBA in prostate cancer models: implications of in vivo stability. J Label Compd Radiopharm. 2019;62(10):646\u201355. https:\/\/doi.org\/10.1002\/jlcr.3733.","journal-title":"J Label Compd Radiopharm."},{"issue":"5","key":"374_CR34","first-page":"823","volume":"46","author":"T Maina","year":"2005","unstructured":"Maina T, Nock BA, Zhang H, Nikolopoulou A, Waser B, Reubi J-C, et al. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med. 2005;46(5):823\u201330.","journal-title":"J Nucl Med"},{"issue":"22","key":"374_CR35","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.3390\/cancers13225766","volume":"13","author":"R Mansi","year":"2021","unstructured":"Mansi R, Nock BA, Dalm SU, Busstra MB, van Weerden WM, Maina T. Radiolabeled bombesin analogs. Cancers (Basel). 2021;13(22):5766.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"374_CR36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.5858\/arpa.2012-0679-OA","volume":"138","author":"J Mattei","year":"2014","unstructured":"Mattei J, Achcar RD, Cano CH, Macedo BR, Meurer L, Batlle BS, et al. Gastrin-releasing peptide receptor expression in lung cancer. Arch Pathol Lab Med. 2014;138(1):98\u2013104. https:\/\/doi.org\/10.5858\/arpa.2012-0679-OA.","journal-title":"Arch Pathol Lab Med"},{"issue":"24","key":"374_CR37","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMc1412654","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Solomon SD. Neprilysin inhibition for heart failure. N Engl J Med. 2014;371(24):2336\u20137. https:\/\/doi.org\/10.1056\/NEJMc1412654.","journal-title":"N Engl J Med"},{"issue":"12","key":"374_CR38","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1002\/ijc.32401","volume":"145","author":"B Mitran","year":"2019","unstructured":"Mitran B, Rinne SS, Konijnenberg MW, Maina T, Nock BA, Altai M, et al. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177Lu-DOTAGA-PEG2-RM26. Int J Cancer. 2019;145(12):3347\u201358. https:\/\/doi.org\/10.1002\/ijc.32401.","journal-title":"Int J Cancer"},{"issue":"41","key":"374_CR39","doi-asserted-by":"publisher","first-page":"7090","DOI":"10.2174\/0929867327666200312114902","volume":"27","author":"B Mitran","year":"2020","unstructured":"Mitran B, Tolmachev V, Orlova A. Radiolabeled GRPR antagonists for imaging of disseminated prostate cancer\u2013influence of labeling chemistry on targeting properties. Curr Med Chem. 2020;27(41):7090\u2013111.","journal-title":"Curr Med Chem"},{"issue":"5","key":"374_CR40","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3390\/cancers13051051","volume":"13","author":"C Montemagno","year":"2021","unstructured":"Montemagno C, Raes F, Ahmadi M, Bacot S, Debiossat M, Leenhardt J, et al. In vivo biodistribution and efficacy evaluation of NeoB, a radiotracer targeted to GRPR mice bearing gastrointestinal stromal tumor. Cancers (Basel). 2021;13(5):1051.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"374_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2174\/1381612033391621","volume":"9","author":"T Moody","year":"2003","unstructured":"Moody T, Chan D, Fahrenkrug J, Jensen R. Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des. 2003;9(6):495\u2013509.","journal-title":"Curr Pharm Des"},{"issue":"9","key":"374_CR42","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2967\/jnumed.116.188011","volume":"58","author":"C Morgat","year":"2017","unstructured":"Morgat C, MacGrogan G, Brouste V, V\u00e9lasco V, S\u00e9venet N, Bonnefoi H, et al. Expression of gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: a study of 1,432 primary tumors. J Nucl Med. 2017;58(9):1401\u20137. https:\/\/doi.org\/10.2967\/jnumed.116.188011.","journal-title":"J Nucl Med"},{"issue":"1","key":"374_CR43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1021\/jm049437y","volume":"48","author":"BA Nock","year":"2005","unstructured":"Nock BA, Nikolopoulou A, Galanis A, Cordopatis P, Waser B, Reubi J-C, et al. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005;48(1):100\u201310. https:\/\/doi.org\/10.1021\/jm049437y.","journal-title":"J Med Chem"},{"issue":"1","key":"374_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2967\/jnumed.113.129411","volume":"55","author":"BA Nock","year":"2014","unstructured":"Nock BA, Maina T, Krenning EP, de Jong M. To serve and protect\u201d: enzyme inhibitors as radiopeptide escorts promote tumor targeting. J Nucl Med. 2014;55(1):121\u20137. https:\/\/doi.org\/10.2967\/jnumed.113.129411.","journal-title":"J Nucl Med"},{"issue":"1","key":"374_CR45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.116.178889","volume":"58","author":"BA Nock","year":"2017","unstructured":"Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, et al. Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results. J Nucl Med. 2017;58(1):75\u201380. https:\/\/doi.org\/10.2967\/jnumed.116.178889.","journal-title":"J Nucl Med."},{"issue":"20","key":"374_CR46","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.3390\/cancers13205093","volume":"13","author":"BA Nock","year":"2021","unstructured":"Nock BA, Kaloudi A, Kanellopoulos P, Janota B, Bromi\u0144ska B, I\u017cycki D, et al. [99mTc]Tc-DB15 in GRPR-targeted tumor imaging with SPECT: from preclinical evaluation to the first clinical outcomes. Cancers (Basel). 2021;13(20):5093.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"374_CR47","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/ph16050674","volume":"16","author":"BA Nock","year":"2023","unstructured":"Nock BA, Kanellopoulos P, Joosten L, Mansi R, Maina T. Peptide radioligands in cancer theranostics: agonists and antagonists. Pharmaceuticals. 2023;16(5):674.","journal-title":"Pharmaceuticals"},{"issue":"4","key":"374_CR48","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3390\/pharmaceutics16040513","volume":"16","author":"K Obeid","year":"2024","unstructured":"Obeid K, Kanellopoulos P, Abouzayed A, Mattsson A, Tolmachev V, Nock BA, et al. GRPR-antagonists carrying DOTAGA-chelator via positively charged linkers: perspectives for prostate cancer theranostics. Pharmaceutics. 2024;16(4):513.","journal-title":"Pharmaceutics"},{"issue":"35","key":"374_CR49","doi-asserted-by":"publisher","first-page":"12891","DOI":"10.1073\/pnas.0711861105","volume":"105","author":"J Qiao","year":"2008","unstructured":"Qiao J, Kang J, Ishola TA, Rychahou PG, Evers BM, Chung DH. Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma. Proc Natl Acad Sci. 2008;105(35):12891\u20136. https:\/\/doi.org\/10.1073\/pnas.0711861105.","journal-title":"Proc Natl Acad Sci"},{"issue":"S1","key":"374_CR50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00428-007-0443-2","volume":"451","author":"JC Reubi","year":"2007","unstructured":"Reubi JC. Peptide receptor expression in GEP-NET. Virchows Arch. 2007;451(S1):47\u201350. https:\/\/doi.org\/10.1007\/s00428-007-0443-2.","journal-title":"Virchows Arch."},{"issue":"7","key":"374_CR51","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00259-002-0794-5","volume":"29","author":"J Reubi","year":"2002","unstructured":"Reubi J, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2002;29(7):855\u201362. https:\/\/doi.org\/10.1007\/s00259-002-0794-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"374_CR52","first-page":"1139","volume":"8","author":"JC Reubi","year":"2002","unstructured":"Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer J-C, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6\u201314). Clin Cancer Res. 2002;8(4):1139\u201346.","journal-title":"Clin Cancer Res."},{"issue":"6","key":"374_CR53","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00259-004-1476-2","volume":"31","author":"JC Reubi","year":"2004","unstructured":"Reubi JC, Kerner M, Waser B, Mazzucchelli L, Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging. 2004;31(6):803\u201310. https:\/\/doi.org\/10.1007\/s00259-004-1476-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"374_CR54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0031-6997(25)00449-1","volume":"45","author":"BP Roques","year":"1993","unstructured":"Roques BP, Noble F, Daug\u00e9 V, Fourni\u00e9-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 1993;45(1):87\u2013146.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"374_CR55","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13550-024-01101-w","volume":"14","author":"C Rottenburger","year":"2024","unstructured":"Rottenburger C, Hentschel M, F\u00fcrstner M, McDougall L, Kottoros D, Kaul F, et al. In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study. EJNMMI Res. 2024;14(1):37. https:\/\/doi.org\/10.1186\/s13550-024-01101-w.","journal-title":"EJNMMI Res."},{"key":"374_CR56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1242\/jcs.1990.Supplement_13.6","volume":"1990","author":"E Rozengurt","year":"1990","unstructured":"Rozengurt E, Fabregat I, Coffer A, Gil J, Sinnett-Smith J. Mitogenic signalling through the bombesin receptor: role of a guanine nucleotide regulatory protein. J Cell Sci. 1990;1990:43\u201356.","journal-title":"J Cell Sci"},{"issue":"13","key":"374_CR57","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1007\/s00259-022-05926-2","volume":"49","author":"EAM Ruigrok","year":"2022","unstructured":"Ruigrok EAM, Verhoeven M, Konijnenberg MW, de Blois E, de Ridder CMA, Stuurman DC, et al. Safety of [177Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity. Eur J Nucl Med Mol Imaging. 2022;49(13):4440\u201351. https:\/\/doi.org\/10.1007\/s00259-022-05926-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"374_CR58","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2967\/jnumed.124.268896","volume":"66","author":"Z Sabahi","year":"2025","unstructured":"Sabahi Z, Nguyen A, Wong K, Li S, Papa N, Lim E, et al. Diagnostic potential of 68Ga-NeoB PET\/CT with estrogen receptor\u2013 and progesterone receptor-positive breast cancer undergoing staging or restaging for metastatic disease. J Nucl Med. 2025;66(5):700\u20136. https:\/\/doi.org\/10.2967\/jnumed.124.268896.","journal-title":"J Nucl Med"},{"issue":"11","key":"374_CR59","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.2967\/jnumed.124.268101","volume":"65","author":"A Saidi","year":"2024","unstructured":"Saidi A, Stallons TA, Wong AG, Torgue JJ. Preclinical investigation of [212Pb]Pb-DOTAM-GRPR1 for peptide receptor radionuclide therapy in a prostate tumor model. J Nucl Med. 2024;65(11):1769\u201375. https:\/\/doi.org\/10.2967\/jnumed.124.268101.","journal-title":"J Nucl Med"},{"issue":"1","key":"374_CR60","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ygeno.2004.01.008","volume":"84","author":"H Sano","year":"2004","unstructured":"Sano H, Feighner SD, Hreniuk DL, Iwaasa H, Sailer AW, Pan J, et al. Characterization of the bombesin-like peptide receptor family in primates. Genomics. 2004;84(1):139\u201346.","journal-title":"Genomics"},{"issue":"1","key":"374_CR61","doi-asserted-by":"publisher","first-page":"27909","DOI":"10.1038\/srep27909","volume":"6","author":"N Schiering","year":"2016","unstructured":"Schiering N, D\u2019Arcy A, Villard F, Ramage P, Logel C, Cumin F, et al. Structure of neprilysin in complex with the active metabolite of sacubitril. Sci Rep. 2016;6(1):27909.","journal-title":"Sci Rep."},{"issue":"3","key":"374_CR62","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2967\/jnumed.122.263889","volume":"64","author":"R Schollhammer","year":"2023","unstructured":"Schollhammer R, Robert G, Asselineau J, Yacoub M, Vimont D, Balamoutoff N, et al. Comparison of 68Ga-PSMA-617 PET\/CT and 68Ga-RM2 PET\/CT in patients with localized prostate cancer who are candidates for radical prostatectomy: a prospective, single-arm, single-center Phase II Study. J Nucl Med. 2023;64(3):379\u201385. https:\/\/doi.org\/10.2967\/jnumed.122.263889.","journal-title":"J Nucl Med."},{"issue":"23","key":"374_CR63","doi-asserted-by":"publisher","first-page":"10662","DOI":"10.1073\/pnas.88.23.10662","volume":"88","author":"MA Shipp","year":"1991","unstructured":"Shipp MA, Tarr GE, Chen CY, Switzer SN, Hersh LB, Stein H, et al. CD10\/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci. 1991;88(23):10662\u20136. https:\/\/doi.org\/10.1073\/pnas.88.23.10662.","journal-title":"Proc Natl Acad Sci"},{"key":"374_CR64","doi-asserted-by":"publisher","first-page":"114497","DOI":"10.1016\/j.biopha.2023.114497","volume":"161","author":"H Sun","year":"2023","unstructured":"Sun H, Ma Q, Bian H, Meng X, Jin J. Novel insight on GRP\/GRPR axis in diseases. Biomed Pharmacother. 2023;161:114497.","journal-title":"Biomed Pharmacother."},{"issue":"1","key":"374_CR65","doi-asserted-by":"publisher","first-page":"S535","DOI":"10.1007\/s00259-024-06939-9","volume":"52","author":"J Urena Poch","year":"2024","unstructured":"Urena Poch J, Al E. Intraindividual comparison of Ga-68-AMTG and Ga-68- PSMA PET\/CT in patients with mCRPC in a theranostic setting. Eur J Nucl Med Mol Imaging. 2024;52(1):S535. https:\/\/doi.org\/10.1007\/s00259-024-06939-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"374_CR66","doi-asserted-by":"publisher","first-page":"10455","DOI":"10.3390\/molecules190710455","volume":"19","author":"Z Varasteh","year":"2014","unstructured":"Varasteh Z, Rosenstr\u00f6m U, Velikyan I, Mitran B, Altai M, Honarvar H, et al. The effect of mini-peg-based spacer length on binding and pharmacokinetic properties of a 68Ga-Labeled NOTA-conjugated antagonistic analog of Bombesin. Molecules. 2014;19(7):10455\u201372.","journal-title":"Molecules"},{"issue":"1","key":"374_CR67","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s11307-023-01851-4","volume":"26","author":"M Verhoeven","year":"2024","unstructured":"Verhoeven M, Haeck J, de Blois E, Orlandi F, Barbato D, Tedesco M, et al. The balance between the therapeutic efficacy and safety of [177Lu]Lu-NeoB in a preclinical prostate cancer model. Mol Imaging Biol. 2024;26(1):114\u201323. https:\/\/doi.org\/10.1007\/s11307-023-01851-4.","journal-title":"Mol Imaging Biol."},{"issue":"1\u20132","key":"374_CR68","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","volume":"15","author":"P Vlieghe","year":"2010","unstructured":"Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov Today. 2010;15(1\u20132):40\u201356.","journal-title":"Drug Discov Today"},{"issue":"13","key":"374_CR69","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.3390\/molecules29133102","volume":"29","author":"L Wang","year":"2024","unstructured":"Wang L, Kuo H-T, Chen C-C, Chapple D, Colpo N, Ng P, et al. Synthesis and evaluation of the first 68Ga-labeled C-terminal hydroxamate-derived gastrin-releasing peptide receptor-targeted tracers for cancer imaging with positron emission tomography. Molecules. 2024;29(13):3102.","journal-title":"Molecules"},{"issue":"2","key":"374_CR70","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2967\/jnumed.124.267810","volume":"66","author":"R Wang","year":"2025","unstructured":"Wang R, Kang W, Liu Z, Zheng Y, Sui H, Li L, et al. Head-to-head comparison of [68 Ga]Ga-NOTA-RM26 and [18F]FDG PET\/CT in patients with gastrointestinal stromal tumors: a prospective study. J Nucl Med. 2025a;66(2):201\u20136. https:\/\/doi.org\/10.2967\/jnumed.124.267810.","journal-title":"J. Nucl. Med."},{"issue":"4","key":"374_CR71","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/RLU.0000000000005651","volume":"50","author":"R Wang","year":"2025","unstructured":"Wang R, Li Y, Li Z, Wang J, Li L, Xiang J, et al. bGastrin-releasing peptide receptor targeting PET\/CT With 68Ga-NOTA-RM26 in the Assessment of glioma and combined multiregional biopsies. Clin Nucl Med. 2025;50(4):316\u201323. https:\/\/doi.org\/10.1097\/RLU.0000000000005651.","journal-title":"Clin Nucl Med"},{"issue":"7","key":"374_CR72","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3390\/ph15070772","volume":"15","author":"K Wong","year":"2022","unstructured":"Wong K, Sheehan-Dare G, Nguyen A, Ho B, Liu V, Lee J, et al. 64Cu-SAR-bombesin PET-CT imaging in the staging of estrogen\/progesterone receptor positive, HER2 negative metastatic breast cancer patients: safety, dosimetry and feasibility in a phase I trial. Pharmaceuticals. 2022;15(7):772.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"374_CR73","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0378-1119(00)00596-5","volume":"264","author":"D Xiao","year":"2001","unstructured":"Xiao D, Wang J, Hampton LL, Weber HC. The human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter. Gene. 2001;264(1):95\u2013103.","journal-title":"Gene"},{"issue":"4","key":"374_CR74","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.bbrc.2013.10.149","volume":"441","author":"B Xu","year":"2013","unstructured":"Xu B, Varasteh Z, Orlova A, Andersson K, Larhammar D, Bj\u00f6rkelund H. Detecting ligand interactions with G protein-coupled receptors in real-time on living cells. Biochem Biophys Res Commun. 2013;441(4):820\u20134.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"374_CR75","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1021\/acs.molpharmaceut.4c00066","volume":"21","author":"Y Zou","year":"2024","unstructured":"Zou Y, Huang M, Hu M, Wang H, Chen W, Tian R. Radiopharmaceuticals targeting gastrin-releasing peptide receptor for diagnosis and therapy of prostate cancer. Mol Pharm. 2024;21(9):4199\u2013216. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00066.","journal-title":"Mol Pharm"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00374-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-025-00374-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00374-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T10:15:52Z","timestamp":1757326552000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-025-00374-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["374"],"URL":"https:\/\/doi.org\/10.1186\/s41181-025-00374-3","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}